Cell Therapy Market (By Use Type: Clinical use, Research use; By Therapy Type: Autologous Therapies, Allogenic Therapies; By End User: Hospitals & Clinics, Academic & Research Institutes; By Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell Therapy Market, by Use Type, 2024-2033
8.1.1. Clinical use
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Research use
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. Cell Therapy Market, by Therapy Type, 2024-2033
9.1.1. Autologous Therapies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Allogenic Therapies
9.1.2.1. Market Revenue and Forecast (2021-2033)
10.1. Cell Therapy Market, by End User, 2024-2033
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Diagnostic centers
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Clinics
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Research institutes
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Regenerative medicine centers
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2021-2033)
11.1. Cell Therapy Market, by Technology, 2024-2033
11.1.1. Viral Vector Technology
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Genome Editing Technology
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Somatic Cell Technology
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Cell Immortalization Technology
11.1.4.1. Market Revenue and Forecast (2021-2033)
11.1.5. Cell Plasticity Technology
11.1.5.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.1.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.3. Market Revenue and Forecast, by End User (2021-2033)
12.1.4. Market Revenue and Forecast, by Technology (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.5.3. Market Revenue and Forecast, by End User (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Technology (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.6.3. Market Revenue and Forecast, by End User (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Technology (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.2.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.3. Market Revenue and Forecast, by End User (2021-2033)
12.2.4. Market Revenue and Forecast, by Technology (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.5.3. Market Revenue and Forecast, by End User (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Technology (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.6.3. Market Revenue and Forecast, by End User (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Technology (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.7.3. Market Revenue and Forecast, by End User (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Technology (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.8.3. Market Revenue and Forecast, by End User (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Technology (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.3.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.3. Market Revenue and Forecast, by End User (2021-2033)
12.3.4. Market Revenue and Forecast, by Technology (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.5.3. Market Revenue and Forecast, by End User (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Technology (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.6.3. Market Revenue and Forecast, by End User (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Technology (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.7.3. Market Revenue and Forecast, by End User (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Technology (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.8.3. Market Revenue and Forecast, by End User (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Technology (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.4.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.3. Market Revenue and Forecast, by End User (2021-2033)
12.4.4. Market Revenue and Forecast, by Technology (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.5.3. Market Revenue and Forecast, by End User (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Technology (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.6.3. Market Revenue and Forecast, by End User (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Technology (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.7.3. Market Revenue and Forecast, by End User (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Technology (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.8.3. Market Revenue and Forecast, by End User (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Technology (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.3. Market Revenue and Forecast, by End User (2021-2033)
12.5.4. Market Revenue and Forecast, by Technology (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.5.3. Market Revenue and Forecast, by End User (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Technology (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Use Type (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.6.3. Market Revenue and Forecast, by End User (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Technology (2021-2033)
13.1. Kolon TissueGene Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. JCR Pharmaceuticals Co. Ltd
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Castle Creek Biosciences Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Anterogen Co. Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Future of Biotechnology
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Celgene Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Tameika Cell Technologies Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Cells for Cells
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. MEDIPOST
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. NuVasive Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample